FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2482126670> ?p ?o ?g. }

• W2482126670 endingPage "2325967116S0012" @default.
• W2482126670 startingPage "2325967116S0012" @default.
• W2482126670 abstract "Objectives: Achilles tendinopathy commonly occurs in both active and inactive persons. It consists in the development of pain and inflammation in the early phases, with progression to the development of fibrotic tissue and degeneration of tendon matrix. Current conservative treatment approaches do not provide sustained satisfactory results, particularly in active patients, although platelet rich plasma (PRP) injection have shown to be effective in many cases. The therapeutic effect of adipose-derived mesenchymal stem cells (ASCs), either expanded or used directly within the stromal vascular fraction (SVF), have demonstrated to possess significant anti-inflammatory and immunomodulatory effects, mediated by the release of active factors, and thus potentially useful in the treatment of tendinopathy. Methods: Patients affected by non-insertional Achilles tendinopathy (range 18-55 y/o) were prospectively enrolled in this controlled study, and randomly assigned either to single PRP injection group (GPSIII kit, Biomet, USA) (n=28 tendons) or single adipose tissue SVF (FastKit, Corios, Italy) (n=28 tendons) injection group. All patients were assessed clinically pre-operatively and at 15, 30, 60, 120 and 180 days from treatment, using VAS Pain, VISA-A, AOFAS and SF-36 forms. Patients also underwent to US and MRI before treatment and then at 4 and 6 month-follow-ups. An aliquot of SVF of each patient was analyzed in vitro for mesenchymal stem cells (MSC) content, viability, proliferation rate, differentiation potential and immunomodulatory ability. Sample size of the study was calculated with a power analysis based on VISA-A score. All the results are expressed as mean ± standard deviation. A Wilcoxon test for paired data was performed to compare variables before and after surgery. Results: Population background data and pre-operative scores were similar in the two groups (p>0.05). At final follow up both patients group showed significantly improvements in all the scores in comparison to baseline (p<0.05). In SVF patients these improvements were faster, with significantly better scores with respect to pre-injection level already starting 15 days after treatment. Indeed at this time point a significant difference between groups in term of VAS, AOFAS and VISA-A score was observed (p<0.05), with better results in the SVF group. After 6 months MR and ultrasounds showed an improvement of clinical signs in both groups, without relevant differences. No side effects were observed in neither groups. In vitro analysis showed a modest content of MSCs in the SVF samples; however these cells were able to efficiently proliferate and differentiate, and to exert good immunomodulatory effect in an in vitro inflammatory model. Conclusion: Both PRP and SVF are safe and effective treatments for Achilles tendinopathy. However, SVF allowed to obtain faster results, thus allowing to consider this treatment particularly suitable for patients requiring to come back to physical activities sooner." @default.
• W2482126670 created "2016-08-23" @default.
• W2482126670 creator A5009085297 @default.
• W2482126670 creator A5011598186 @default.
• W2482126670 creator A5060011330 @default.
• W2482126670 creator A5063397823 @default.
• W2482126670 creator A5080455707 @default.
• W2482126670 creator A5081532146 @default.
• W2482126670 date "2016-07-01" @default.
• W2482126670 modified "2023-10-16" @default.
• W2482126670 title "Treatment of Achilles Tendinopathy with Autologous Adipose-derived Stromal Vascular Fraction" @default.
• W2482126670 doi "https://doi.org/10.1177/2325967116s00128" @default.
• W2482126670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4968303" @default.
• W2482126670 hasPublicationYear "2016" @default.
• W2482126670 type Work @default.
• W2482126670 sameAs 2482126670 @default.
• W2482126670 citedByCount "9" @default.
• W2482126670 countsByYear W24821266702017 @default.
• W2482126670 countsByYear W24821266702019 @default.
• W2482126670 countsByYear W24821266702020 @default.
• W2482126670 countsByYear W24821266702021 @default.
• W2482126670 countsByYear W24821266702022 @default.
• W2482126670 crossrefType "journal-article" @default.
• W2482126670 hasAuthorship W2482126670A5009085297 @default.
• W2482126670 hasAuthorship W2482126670A5011598186 @default.
• W2482126670 hasAuthorship W2482126670A5060011330 @default.
• W2482126670 hasAuthorship W2482126670A5063397823 @default.
• W2482126670 hasAuthorship W2482126670A5080455707 @default.
• W2482126670 hasAuthorship W2482126670A5081532146 @default.
• W2482126670 hasBestOaLocation W24821266701 @default.
• W2482126670 hasConcept C126322002 @default.
• W2482126670 hasConcept C126894567 @default.
• W2482126670 hasConcept C141071460 @default.
• W2482126670 hasConcept C142724271 @default.
• W2482126670 hasConcept C16930146 @default.
• W2482126670 hasConcept C171089720 @default.
• W2482126670 hasConcept C198826908 @default.
• W2482126670 hasConcept C2778911562 @default.
• W2482126670 hasConcept C2780076745 @default.
• W2482126670 hasConcept C2780105995 @default.
• W2482126670 hasConcept C2780745355 @default.
• W2482126670 hasConcept C2780984734 @default.
• W2482126670 hasConcept C28328180 @default.
• W2482126670 hasConcept C54355233 @default.
• W2482126670 hasConcept C71924100 @default.
• W2482126670 hasConcept C86803240 @default.
• W2482126670 hasConcept C89560881 @default.
• W2482126670 hasConceptScore W2482126670C126322002 @default.
• W2482126670 hasConceptScore W2482126670C126894567 @default.
• W2482126670 hasConceptScore W2482126670C141071460 @default.
• W2482126670 hasConceptScore W2482126670C142724271 @default.
• W2482126670 hasConceptScore W2482126670C16930146 @default.
• W2482126670 hasConceptScore W2482126670C171089720 @default.
• W2482126670 hasConceptScore W2482126670C198826908 @default.
• W2482126670 hasConceptScore W2482126670C2778911562 @default.
• W2482126670 hasConceptScore W2482126670C2780076745 @default.
• W2482126670 hasConceptScore W2482126670C2780105995 @default.
• W2482126670 hasConceptScore W2482126670C2780745355 @default.
• W2482126670 hasConceptScore W2482126670C2780984734 @default.
• W2482126670 hasConceptScore W2482126670C28328180 @default.
• W2482126670 hasConceptScore W2482126670C54355233 @default.
• W2482126670 hasConceptScore W2482126670C71924100 @default.
• W2482126670 hasConceptScore W2482126670C86803240 @default.
• W2482126670 hasConceptScore W2482126670C89560881 @default.
• W2482126670 hasIssue "7_suppl4" @default.
• W2482126670 hasLocation W24821266701 @default.
• W2482126670 hasLocation W24821266702 @default.
• W2482126670 hasLocation W24821266703 @default.
• W2482126670 hasOpenAccess W2482126670 @default.
• W2482126670 hasPrimaryLocation W24821266701 @default.
• W2482126670 hasRelatedWork W2258510783 @default.
• W2482126670 hasRelatedWork W2321698694 @default.
• W2482126670 hasRelatedWork W2327906432 @default.
• W2482126670 hasRelatedWork W2482126670 @default.
• W2482126670 hasRelatedWork W2593595608 @default.
• W2482126670 hasRelatedWork W3034030555 @default.
• W2482126670 hasRelatedWork W3156848835 @default.
• W2482126670 hasRelatedWork W3210506080 @default.
• W2482126670 hasRelatedWork W4321456914 @default.
• W2482126670 hasRelatedWork W4379197218 @default.
• W2482126670 hasVolume "4" @default.
• W2482126670 isParatext "false" @default.
• W2482126670 isRetracted "false" @default.
• W2482126670 magId "2482126670" @default.
• W2482126670 workType "article" @default.